Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AvantorMEX:AVTR 67 Debt-to-Equity is 0.66 as of Jun. 2026, which is 45% below its 10-year median of 1.19. GuruFocus rates MEX:AVTR with a GF Score™ of 67/100 and a GF Value™ of MXN303.26. The stock has 4 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Avantor ranks worse than 76.91% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Avantor's Debt-to-Equity or its related term are showing as below:
MEX:AVTR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.72 Med: 1.19 Max: 2.21
Current: 0.66
During the past 10 years, the highest Debt-to-Equity Ratio of Avantor was 2.21. The lowest was -2.72. And the median was 1.19.
MEX:AVTR's Debt-to-Equity is ranked worse than 76.91% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs MEX:AVTR: 0.66
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Avantor Debt-to-Equity Related Terms
Avantor Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Avantor's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AVTR vs RGEN, ATR, TFX: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Avantor's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avantor Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avantor's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Avantor's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avantor (MEX:AVTR) has a Debt-to-Equity of 0.66 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avantor and its competitors. This is 45% below median its historical median of 1.19. According to the industry distribution chart, Avantor ranks #543 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 76.9%.
Is Avantor's Debt-to-Equity too high?
Avantor's current Debt-to-Equity of 0.66 is 45% below median its 10-year median of 1.19. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Avantor's value of 0.66 is 187% above this industry median. Based on the distribution chart, Avantor ranks #543 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avantor has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Avantor's Debt-to-Equity compare to RGEN and ATR?
According to the Medical Devices & Instruments industry distribution chart, Avantor ranks #543 out of 706 companies for Debt-to-Equity. This places Avantor in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Avantor's value of 0.66 is 187% above this benchmark. While the company's 10-year median is 1.19 vs. the industry median of 0.23, Avantor has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avantor's current Debt-to-Equity of 0.66 is 187% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avantor and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avantor's current Debt-to-Equity is 0.66, which is 45% below median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avantor stock overvalued right now?
Avantor (MEX:AVTR) has a current Debt-to-Equity of 0.66. The stock's GF Value™ is MXN303.26, compared to a current price of MXN244.00 — trading 19.5% below its estimated fair value. The current Debt-to-Equity is 0.66, which is 45% below median its 10-year median of 1.19 and 187% above the Medical Devices & Instruments industry median of 0.23. Avantor's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Avantor (MEX:AVTR), the current Debt-to-Equity is 0.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avantor (MEX:AVTR) Overvalued in 2026?
Based on GuruFocus' analysis, Avantor stock appears to be undervalued.
The current stock price of MXN244.00 is trading 19.5% below its estimated GF Value™ of MXN303.26.
Key valuation signals for MEX:AVTR:
Debt-to-Equity: 0.66 (45% below median its 10-year median of 1.19)
GF Value™: MXN303.26 vs. price of MXN244.00 (19.5% below fair value)
Industry Position: 187% above the Medical Devices & Instruments median (#543 of 706)
No single metric tells the full story. See the MEX:AVTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
67GF Score
Get the complete analysis for MEX:AVTR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AVTR has been successfully added to your 
